Literature DB >> 17637014

Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership.

Yongsheng Yang1, Patrick J Faustino, Donna A Volpe, Christopher D Ellison, Robbe C Lyon, Lawrence X Yu.   

Abstract

The purpose of this study was to determine the permeability and solubility of seven beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, sotalol, and timolol) and to classify them according to the Biopharmaceutics Classification System (BCS). Apparent permeability coefficients (Papp) were measured using the Caco-2 cell line, and the solubility was determined at 37 degrees C over a pH range of 1.0-7.5. The permeability coefficients ranged from 1.0x10(-7) to 4.8x10(-5) cm/s. On the basis of the in vitro permeability and solubility data observed in the study, labetolol, metoprolol, and timolol can be categorized as BCS Class I drugs, whereas acebutolol, atenolol, and nadolol belong to BCS Class III. The permeability coefficients in Caco-2 cells were consistent with the reported extent of intestinal absorption in humans for all drugs except sotalol. Sotalol displayed low permeability in the Caco-2 cell line, but the extent of intestinal absorption in humans is over 90%. The low permeability through the Caco-2 monolayers might be largely related to its low lipophilicity. In addition, the difference between the tightness of the intercellular junction in vivo and in vitro may partially contribute to this disparity in the sotalol permeability of in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637014     DOI: 10.1021/mp070028i

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  20 in total

Review 1.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

Review 2.  Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.

Authors:  Arik Dahan; Jonathan M Miller; Gordon L Amidon
Journal:  AAPS J       Date:  2009-10-30       Impact factor: 4.009

3.  The BCS, BDDCS, and regulatory guidances.

Authors:  Mei-Ling Chen; Gordon L Amidon; Leslie Z Benet; Hans Lennernas; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

4.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 5.  Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective.

Authors:  Guo Yu; Qing-Shan Zheng; Guo-Fu Li
Journal:  AAPS J       Date:  2014-09-03       Impact factor: 4.009

6.  Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.

Authors:  Le Sun; Jin Sun; Zhonggui He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 7.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

8.  Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.

Authors:  Feras Khalil; Stephanie Läer
Journal:  AAPS J       Date:  2014-01-08       Impact factor: 4.009

9.  Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.

Authors:  Tuba Incecayir; Yasuhiro Tsume; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

10.  Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.

Authors:  Angela Villiger; Cordula Stillhart; Neil Parrott; Martin Kuentz
Journal:  AAPS J       Date:  2016-04-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.